MedeliX
Start asking

dulaglutide

Trulicity · ATC code A10BJ05

Also known as: Dulaglutid

Key facts
Active substance
dulaglutide
Drug class
Glucagon-like peptide-1
ATC code
A10BJ05
Authorisation
centrally authorised across the EU (EMA)
Dosage forms
Trulicity 0.75 mg solution for injection in pre-filled pen / Trulicity 1.5 mg solution for injection in pre-filled pen / Trulicity 3 mg solution for injection in pre-filled pen
Marketing authorisation holder
Eli Lilly Nederland B.V.
Information as of
2026-10-27

Key facts

Dulaglutide is a once-weekly injected GLP-1 receptor agonist (Trulicity). It is used for insufficiently controlled type 2 diabetes in patients 10 years and above, as an adjunct to diet and exercise.

What it is used for

  • Type 2 diabetes in patients 10 years and above, adjunct to diet and exercise
  • As monotherapy when metformin is inappropriate
  • In addition to other diabetes medicines

Dosing

  • Adults, monotherapy: 0.75 mg once weekly
  • Adults, add-on therapy: 1.5 mg once weekly; if needed after at least 4 weeks 3 mg, then 4.5 mg; maximum 4.5 mg weekly
  • Children 10 years and above: start 0.75 mg weekly, if needed 1.5 mg after at least 4 weeks (maximum)
  • With a sulphonylurea or insulin: consider reducing their dose (hypoglycaemia risk)
  • Missed dose: take if at least 3 days (72 hours) remain until the next dose
  • No dose adjustment for age, hepatic or renal impairment; not recommended in end stage renal disease

Contraindications

  • Hypersensitivity to the active substance or any of the excipients

Important warnings

  • Not for type 1 diabetes or diabetic ketoacidosis; not a substitute for insulin
  • Ketoacidosis reported after rapid discontinuation or dose reduction of insulin
  • Not recommended in severe gastrointestinal disease including severe gastroparesis
  • Pulmonary aspiration risk with general anaesthesia or deep sedation due to delayed gastric emptying
  • Dehydration from gastrointestinal adverse reactions

Side effects

  • Most frequent: gastrointestinal, including nausea, vomiting and diarrhoea
  • Generally mild or moderate and transient
  • Hypoglycaemia in combination with sulphonylureas or insulin

Interactions

  • Delayed gastric emptying may affect absorption of oral medicines, particularly at treatment initiation
  • Potential altered exposure for oral medicines with rapid absorption or prolonged release

Pregnancy and breastfeeding

  • Not recommended during pregnancy
  • Should not be used during breast-feeding

Summary of the official product information, written with AI (Claude, Anthropic) on 2026-10-28. Every number was checked automatically against the original text. Not reviewed by a physician – the full official text is authoritative.

Full official text →

Common questions – ask Medelix

For patients

Package leaflet, verbatim

Package leaflet for patients →

Authorisation and brand names by country

Medicines with exactly this active-substance composition, as listed in the national registers – alphabetical and without ranking. Whether a product is currently available is not shown here.

EU – centrally authorised (all member states)

  • TrulicityEli Lilly Nederland B.V. · EMEA/H/C/002825

Source: European Medicines Agency (EMA), product information

Turkey

  • TrulicityLİLLY İLAÇ TİC. LTD. ŞTİ. · 4 register entries

Source: TİTCK – Ruhsatlı Beşeri Tıbbi Ürünler Listesi, as of 2026-10-16

Brand names in 3 more European countries
Iceland
Trulicity
Liechtenstein
Trulicity
Norway
Trulicity

EMA – Article 57 product data (EU/EEA), 2026-10-28

Medelix receives no money from pharmaceutical companies. Brand names are listed alphabetically and without ranking.

Other substances in the same group

Related calculators

Another question about this substance?

Medelix answers clinical questions from guidelines, studies and product information – every claim with its source.

Sources

  1. European Medicines Agency. Trulicity – EPAR, Product Information (OF THE TEXT Detailed information on this medicinal product i). 2026-10-27. https://www.ema.europa.eu/en/documents/product-information/trulicity-epar-product-information_en.pdf
  2. TİTCK – Ruhsatlı Beşeri Tıbbi Ürünler Listesi, 2026-10-16. https://www.titck.gov.tr/dinamikmodul/85
  3. Wikidata (CC0): ATC A10BJ.

Editorial: Medelix editorial team · last updated 2026-10-27 · How these pages are made · Report an error

Source: European Medicines Agency (EMA), product information. Not advertising, not a treatment recommendation. For questions about your own treatment, ask your doctor or pharmacist.